WASHINGTON — In a closed-door meeting Thursday morning, Sen. Mitt Romney (R-Utah) warned the trade group for the United States’ largest drug companies that he and his new colleagues are working to address high prescription drug prices — and that the industry should participate in those discussions.

“My view was that there is going to be change with regards to pharmaceutical pricing and that I think they would be wise to try and shape the reforms as opposed to hoping nothing will happen, because I think some change is coming,” Romney told STAT in a brief interview this afternoon, when asked about his message to the board of directors for PhRMA, the trade association that represents companies like Amgen (AMGN), Gilead, and Eli Lilly.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I’m lucky that I have good healthcare but I know someone very well who
    has an existing condition who pays an outrageous price to buy healthcare
    and still has to pay the first $6000.00 Hope Romney has success reducing
    prices.

  • This should leave no doubt as to why Americans pay more for prescription drugs and ineficiaent healthcare, than any otehr developed nation. Romney seems unaware that the American people are catching on to how these corrupt politicians are in bed with the industry.
    phRMA also “educates” journalists and PR people at lavish conventions. That way they can get positive uncritial coverage in major newspapers, and medical websites.

  • Awesome because I consider Healthcare, in particular, prescription drugs, a nation not emergency, that I consider acute, but deplorable condition in an otherwise supposedly progressive country. Many in Europe, incl. My home country are shaking their heads in disbelief

  • When did this guy turn into an idiot. Outrageous cost for FDA approval, mountains of red tap to market, and ridiculous lawsuits perpetuated by all the government lawyers and old Mitt wants to put the screws to the drug companies? Instead of pounding them so they stop producing new lifesaving drug, how about tort reform and streamlining the approval process. Attacking big pharma will make mattered much worse.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy